Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses how new findings highlight the need for simplified decision-making in lipid management and a stronger focus on achieving LDL-C targets ...

Patients Getting Weight Loss Information from Advertising as Opposed to Doctors: New Study Suggests ...

Patients Getting Weight Loss Information from Advertising as Opposed to Doctors: New Study Suggests ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions. A new product launch represents one of ...

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines. Novo Nordisk and Septerna have ...